Clinical Trial Update: Gefitinib Usage and Outcomes in Routine Treatment

View source ↗

Summary

A completed clinical trial conducted by AstraZeneca evaluated the use and outcomes of Gefitinib in routine treatment for lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer

Drugs mentioned

• Gefitinib (Iressa) (gefitinib)

Snippet

Sponsor: AstraZeneca | Conditions: Lung Cancer | Status: COMPLETED